Testing and typing of eicosanoid-patterns

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 12, 2006, Pages 47-64

  Schäfer, Dirk ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Functional Eicosanoid Typing, (FET); In vitro test; Inflammatory diseases; Total Eicosanoid Pattern score (TEP)

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ICOSANOID; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEUROPEPTIDE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SUBSTANCE P;

ADULT; AGED; CELL FUNCTION; CELL SEPARATION; CONFERENCE PAPER; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG EFFECT; FATTY ACID SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; ICOSANOID METABOLISM; IN VITRO STUDY; INFLAMMATORY DISEASE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; PROVOCATION TEST; SCORING SYSTEM;

ADULT; AGED; ANALGESICS; ARACHIDONIC ACID; ASPIRIN; DINOPROSTONE; EICOSANOIDS; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES; LEUKOTRIENES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 34147118490     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Bergström B. Prostaglandines: Members of a new hormonal system. Science 1967; 157: 323-390.
2. Pompeia C, Procopio J, Curi R. Fatty acids and immune system. Barz J Pharm Sci 1999; 35: 166-194.
3. Vane JR & Botting RM. Biological properties of cyclooxygenase products. In Lipid mediators FM Cunningham (ed.) Academic Press, London 1994, pp. 61-97.
4. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-1176.
5. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989; 259: 315-324.
6. Chilton FH, Fonteh AN, Surette ME, Triggiani M, Winkler JD. Control of arachidonate levels within inflammatory cells. Biochim Biophys Acta 1996; 1299: 1-15.
7. Murphy DJ. The biogenesis and function of lipid bodies in animal, plants and microorganisms. Prog Lipid Res 2001; 40: 325-438.
8. Dvorack AM, Dvorak HF, Peters SP, et al. Lipid bodies: cytoplasmatic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol 1983; 131: 2965-2976.
9. Weller PF & Dvorack AM. Lipid bodies: intracellular sites for eicosanoid formation. J Allergy Clin Immunol 1994; 95: 1151-1156.
10. Bozza PT, Yu W, Penrose JF, Morgan ES, Dvorak AM, Weller PF. Eosinophil lipid bodies: specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med 1997; 186: 909-920.
11. Schäfer D & Baenkler HW. Functional eicosanoid test and typing (FET) of peripheral blood cells in eicosanoid related disaeses. J Physiol Pharmacol 2005; 56: Suppl 5: 103-118.
12. Baenkler HW, Schäfer D, Hosemann W. Eicoanoid pattern in nasal polyps and nasal mucosa. Rhinology 1996; 34: 166-170.
13. 2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. Thorax 1996; 51: 919-932.
14. Schäfer D, Schmid M, Göde U, Baenkler HW. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999; 13: 638-646.
15. Schmid M, Göde U, Schäfer D, Wiegand ME. Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Act Otholaryngol (Stockholm) 1999; 199: 277-280.
16. Gosepath J, Hoffmann F, Schäfer D, Amedee RG, Mann WJ. Aspirin Intolerance in patients with chronic sinusitis. ORL J Othorinolaryngol Relat Spec 1999; 61: 146-150.
17. Kaldenbach T, Schäfer D, Gosepath J, Bittinger F, Klimek L, Mann WJ. Die Bedeutung eosinophiler Granulocyten in Beziehung zu Allergie und Aspirin-Intoleranz bei Patienten mit Sinusitis polyposa. Laryngo Rhino Otol 1999; 78: 429-434.
18. Gosepath J, Schäfer D, Amedee RG, Mann WJ. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg 2001; 127: 316-321.
19. Gosepath J, Schäfer D, Mann WJ. Analgetika-Intoleranz: Langzeitergebnisse bis zu 3 Jahren bei adaptativer Desaktivierung mit einer täglichen Erhaltungsdosis von 100 mg Aspirin. Laryngo-Rhino-Otol 2002; 81: 732-738.
20. Hecksteden K, Schäfer D, Stuck BA, Klimek L, Hörmann K. Diagnostik des Analgetika-Intoleranz-Syndroms mittels funktioneller Zelltestung (Analgetika-Intoleranz-Test: AIT). Allergologie 2003; 26: 263-271.
21. Baenkler HW, Zeus J, Schenk J, Schäfer D. Abnormal eicosanoid pattern by blood leukocytes in gastroduodenal ulcer. Med Sci Monit 2004; 10: CR447-556.
22. Baenkler HW, Schäfer D. Abnormal eicosanoid-pattern of peripheral white-blood-cells in gastro-intestinal cancer. J Physiol Pharmacol 2005; 56: Suppl 5:119-128.
23. Velten F, Bayerl C, Baenkler HW, Schaefer D. Functional eicosanoid test and typing (FET) in acetylsalicylic acid intolerant patients with urticaeia. J Physiol Pharmacol 2006; 57: Suppl 12:
24. von Euler US. Über die spezifische blutdrucksenkende Substanz des menschlichen Prostataund Samenblasensekretes. Klin Wschr 1935; 14: 1182-1186.
25. Ader R (ed.). Psychoneuroimmunology. Academic Press, Orlando, 1981.
26. Besedovsky HO, Rey A. Immuno-neuro-endocrine interactions: facts and hypothesis. Endocrine Rev 1996: 17: 64-102.
27. Barrett KE. Bidirectional communication between mast cells and nerves controls intestinal secretion. Gastroenterology 1999; 101: 1134-1136.
28. Stead RH, Bienenstock J, Stanisz AM. Neuropeptide regulation of mucosal immunity. Immunol Rev 1987; 100: 333-359.
29. Payan DG, Brewster DR, Missirian-Bastian A, Goetzl EJ. Substance P recognition by subset of human T-lymphocytes. J Clin Invest 1984; 74: 1532-1539.
30. Mayer M. Leukotrienes and other lipoxygenase metabolites of arachidonic acid: their role in edema, ischemia and demyelination of the central nervous system. Acta Univ Palacki Olomuc Fac Med 1988; 119: 181-186.
31. Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 1998; 30: 5-11.
32. Keeble MS, Brain SD. A role for substance P in arthitis? Neurosci Lett 2004; 361: 176-179.
33. Sauer SK, Schäfer D, Kress M, Reeh PW. Stimulated prostaglandin E2 from rat skin, in vitro. Life Sci 1998; 62: 2045-2055.
34. Humes JL, Sadowski S, Galavage M, et al. Evidence for two sources of arachidonic acid for oxidative metabolism by mouse peritoneal macrophages. J Biol Chem 1982; 257: 1591-1594.
35. Marcus AJ. Eicosanoids: transcellular metabolism. In Inflammation: Basic principles and clinical correlates. Gallin JI, Goldstein IM, Snyderman T (eds.), New York, Raven Press 1988, pp. 129-137.
36. Phipps RP. A new view of prostaglandin E regulation of the immune response. Immunology Today 1991; 12: 351-352.
37. Robert A, Nezamis JE, Lancaster C, et al. Cytoprotection by prostaglandins in rat. Prevention of gastric necrosis produced by alcohol, HCL, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77: 433-444.
38. Rampton DS, Sladen GE, Youlton LY. Rectal mucosal prostaglandin E2 release and its relation to disease activity; electrical potential differences and treatment in ulcerative colitis. Gut 1980; 21: 591-596.
39. Pavord ID, Tatersfield AE. Bronchoprotective role of endogenous prostaglandin E2. Lancet 1995; 345: 436.
40. Chung KF. Leukotriene receptor anatagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1985; 8: 1203-1213.
41. Larssen JS, Acista EP. Leukotreine-receptor antagonists and 5-lipoxygenase inhibitors in asthma. Ann Pharmacotherapy 1993; 27: 898-903.
42. Beckett PA, Howarth PH. Pharmacotherapy and airway remodelling in asthma? Thorax 2006; 58: 163-174.
43. Vargaftif BB, Singer M. Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol 2003; 28: 410-419.
44. Morlion BJ, Torwesten E, Kuhn K, Puchstein C, Fürst P. Cysteinyl-leukotriene generation as biomarker for survival in the critically ill. Crit Care Med 2000; 28: 3655-3658.
45. Cohn LA, Adler KB. Interactions between airway epithelium and mediators of inflammation. Exp Lung Res 1992; 18(3): 299-322.
46. Holtzman MJ, Pentland A, Baenziger NL, Hansbrough JR. Heterogeneity of cellular expression of arachidonate 15-lipoxygenase: implications for biological activity. Biochim Biophys Acta 1989; 1003(2): 204-208.
47. Kloprogge E, Leeuw AJ, Monchy JGR, Kaufman HF. Cellular communication in leukotriene C4 production between eosinophils and neutrophils. J Allergy Clin Immunol 1989; 83: 393-400.
48. Abraham WM. The interaction among granulocyte lipid mediators and the generation of oxygen radicals in antigen-induced airway hyperresponsiveness. Adv Prostaglandin Thromboxane Leukot Res 1994; 22: 131-140.
49. Ham ED, Sodermann DD, Zanetti ME, Doughgerry HW, McCauley E, Kuehl FA. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci USA 1993; 80: 1349-1353.